Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients.

Saved in:
Bibliographic Details
Title: Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients.
Authors: Lim, Endry H. T.1,2 (AUTHOR) e.lim@amsterdamumc.nl, Vlaar, Alexander P. J.1 (AUTHOR), de Bruin, Sanne1 (AUTHOR), Rückinger, Simon3 (AUTHOR), Thielert, Claus4 (AUTHOR), Habel, Maria5 (AUTHOR), Guo, Renfeng6 (AUTHOR), Burnett, Bruce P.6 (AUTHOR), Dickinson, James4 (AUTHOR), Brouwer, Matthijs C.2 (AUTHOR), Riedemann, Niels C.5 (AUTHOR), van de Beek, Diederik2 (AUTHOR), Witzenrath, Martin (AUTHOR), van Paassen, Pieter (AUTHOR), Heunks, Leo M. A. (AUTHOR), Mourvillier, Bruno (AUTHOR), Tuinman, Pieter R. (AUTHOR), Saraiva, José Francisco K. (AUTHOR), Marx, Gernot (AUTHOR), Lobo, Suzana M. (AUTHOR)
Source: Intensive Care Medicine Experimental. 6/19/2023, Vol. 11 Issue 1, p1-13. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:2197425X
DOI:10.1186/s40635-023-00520-8